Immuron Ltd — Regulatory Filings 2017

Oct 31, 2017

NT 20-F 1 s107927_nt20f.htm NT 20-F

| UNITED
STATES SECURITIES
AND EXCHANGE COMMISSION Washington,
D.C. 20549 FORM
12b-25 NOTIFICATION
OF LATE FILING | OMB
APPROVAL |
| --- | --- |
| | OMB
Number: 3235-0058 Expires:
October 31, 2018 Estimated
average burden hours
per response .....2.50 |
| | SEC
FILE NUMBER 001-38104 |
| (Check
One) ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐
Form N-SAR ☐ Form N-CSR | CUSIP
NUMBER 45254U
10 1 |
| For
Period Ended: June 30, 2017 ☐ Transition
Report on Form 10-K ☐
Transition Report on Form 20-F ☐ Transition
Report on Form 11-K ☐
Transition Report on Form 10-Q ☐ Transition
Report on Form N-SAR For
the Transition Period Ended: _________ | |
| Read
Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein. | |
| If
the notification relates to a portion of the filing checked above, identify the Item(s)
to which the notification relates: | |
| PART
I – REGISTRANT INFORMATION | |
| IMMURON
LIMITED Full
Name of Registrant | |
| N/A Former
Name if Applicable | |
| Level
3, 62 Lygon Street, Carlton South Address
of Principal Executive Office ( Street and Number) Victoria,
3053, Australia 3053 City,
State and Zip Code | |
| PART
II – RULES 12b-25(b) AND (c) If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate) | |

| ☒ |
| --- |
| (b) The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due date; and |
| (c) The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

Persons who are to respond to the collections of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1344 (04-09)

Field: Page; Sequence: 1

Field: /Page

PART III – NARRATIVE State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. The “Registrant” was unable, without unreasonable effort or expense, to file its Annual Report on Form 20-F for the year ended June 30, 2017 by the October 30, 2017, filing date due to unexpected difficulties encountered in completing the review of the report prior to filing. The Registrant anticipates that it will file the Annual Report no later than the 15th calendar day following the prescribed filing date.

| PART
IV – OTHER INFORMATION (1) Name
and telephone number of person to contact in regard to this notification Peter
Vaughan/ Jerry Kanellos +61
(0)3 9824 5254 (Name)
(Area
Code) (Telephone Number) |
| --- |
| (2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act
of 1934 or Section 30 of the Investment Registrant Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed?
If answer is no, identify report(s). ☒ Yes ☐ No |
| (3) Is
it anticipated that any significant change in results of operations from the corresponding period for the
last fiscal year will be reflected by the earnings statements to be included in the subject report or portion
thereof? ☐
Yes ☒ No If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made. |
| IMMURON
LIMITED (Name
of Registrant as Specified in Charter) has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized. |

Date: October 31, 2017
Peter Vaughan, Joint Chief Financial
Officer and Company Secretary

INSTRUCTION: The form may be signed by an executive officer of the Registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

Field: Page; Sequence: 1; Options: Last

Field: /Page